The study will focus on relieving abdominal pain in IBS patients over 21 through psychotherapy. It will measure effects on patients at four weeks, six months and 12 months.
The study will be led by MGH pediatric gastroenterology fellow Erin Mauney, MD.
“We are delighted to be partnering with Tryp Therapeutics, a recognized leader in the development of psilocybin-assisted therapies,” Dr. Mauney said in a Jan. 3 press release. “There is tremendous potential for the treatment of debilitating IBS and other disorders of gut-brain interaction by utilizing the combined administration of psilocybin and psychotherapy.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
